Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases
Clear cell (CC) and papillary serous carcinoma (PS) are histotypes at high risk of recurrence. We analyse patients’ survival in a retrospective series of 128 CC and PS endometrial cancer cases.
All women with a histologically confirmed CC and PS endometrial cancer who underwent primary surgery in five institutions in Lombardy, Italy, were eligible for this study. A total of 77 (60.2 %) were PS endometrial cancer cases, 45 (35.2 %) CC cases and 6 (4.6 %) cases had mixed CC and PS histotype.
54 (42 %) cases were diagnosed at stage I, 10 (8 %) at stage II, 47 (37 %) at stage III and 17 (13 %) at stage IV. Recurrence was observed in 49 cases (38.3 %). The median time at recurrence was 12 months (interquartile range 7–18). The rate of recurrence was 20.3 % in cases at stage I–lI and 56.2 % in cases at stage III–IV (p < 0.0001). With regard to the site of recurrence 24 recurrences were in and 52 outside the pelvis. Finally, the rate of recurrence was 32.6 % (14 cases) in CC cases, 43.1 % (31 cases) in PS cases and 66.7 % (4 cases) in cases with mixed histotype. The 5-year progression-free survival was 59.5 % (67.4 % for CC cases, 55.1 % for PS and mixed cases).
In this study including CC and PS endometrial cancers, the 5-year survival from surgery was 72.7 % and the 5-year progression-free survival was 59.5 %.
KeywordsEndometrial cancer Histotype Survival
Conflict of interest
No conflict of interest is declared.
- 9.Fader AN, Drake RD, O’Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, Gehrig PA, Tuller E, Axtell AE, Zanotti KM (2009) Platinum/taxanebased chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 115:2119–2127PubMedCrossRefGoogle Scholar
- 15.Huh WK, Powell M, Leath CA 3rd, Straughn JM Jr, Cohn DE, Gold MA, Falkner CA, Carey DE, Herzog T, Fowler JM, Partridge EE, Kilgore LC, Alvarez RD (2003) Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 91:470–475PubMedCrossRefGoogle Scholar
- 19.Randall ME, Brunetto G, Muss H et al (2003) Whole abdominal radiotherapy versus combinationdoxorubicin–cisplatin chemotherapy in avanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. [Abstract]. Proc Am Soc. Clin Oncol 22:2Google Scholar
- 22.Steed H, Manchul L, Rosen B, Fyles A, Lockwood G, Laframboise S, Murphy J, Milosevic M, Chapman W, Oza AM (2006) Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy. Int J Gynecol Cancer 16(Suppl 1):278–285PubMedCrossRefGoogle Scholar